Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions-Reference-Cited by-同舟云学术

Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions

Published:2020-08 Issue: Volume:222 Page:532-533
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Gannon Jessica M.,Conlogue Judith,Sherwood Robin,Nichols Jessica,Ballough Juliette R.,Fredrick Noreen M.,Chengappa K.N. Roy

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference4 articles.

1. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder;Greene;J. Med. Econ.,2018

2. Long-acting injectable antipsychotics treatment during COVID-19 pandemic – a new challenge;Ifteni;Schizophr. Res.,2020

3. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies;Kishimoto;J Clin Psychiatry,2013

4. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge;Marcus;J Manag Care Spec Pharm,2015

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the impact of COVID-19 on medication adherence and health care utilization among individuals with psychotic disorders who are prescribed long-acting injectables (LAIs) or clozapine: A population-based study in Manitoba, Canada;Schizophrenia Research;2024-09

2. Long‐acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID‐19 pandemic: A micro‐narrative review;Neuropsychopharmacology Reports;2024-01-06

3. Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study;Neuropsychiatric Disease and Treatment;2023-04

4. The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia;Neuropsychiatric Disease and Treatment;2023-03

5. Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic;Neuropsychiatric Disease and Treatment;2023-03